Results 41 to 50 of about 44,829 (223)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade

OncoImmunology, 2022
Interferon gamma (IFNG/IFNγ)-induced adaptive immune resistance remains a challenge for tumor therapy. We observed that the chaperone heat shock protein 90 (HSP90) stabilizes the transcription factor signal transducer and activator of transcription 1 ...
Jiao Liu, Rui Kang, Guido Kroemer, Daolin Tang   +3 more
doaj   +1 more source

The role of placental tryptophan catabolism

Frontiers in Immunology, 2014
This review discusses the mechanisms and consequences of degradation of tryptophan (Trp) in the placenta, focussing mainly on the role of indoleamine 2,3-dioxygenase-1 (IDO1), one of three enzymes catalyzing the first step of the kynurenine pathway of ...
Peter eSedlmayr, Astrid eBlaschitz, Roland eStocker   +2 more
doaj   +1 more source

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers

Frontiers in Oncology, 2018
Recent application of immunotherapy in clinical oncology revolutionized our management of advanced human cancers. Check point inhibitors targeting CTLA4 and PD-1/PD-L1 axis are immunotherapeutic agents currently available to treat a variety of cancers ...
T. Komiya, C. Huang
semanticscholar   +1 more source

The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders [PDF]

, 2013
Understanding the neurochemical basis for cognitive function is one of the major goals of neuroscience, with a potential impact on the diagnosis, prevention and treatment of a range of psychiatric and neurological disorders.
Akagbosu, Akladios, Alexander, Alkondon, Alkondon, Alkondon, Amori, Andersen, Atlas, Autier, Backman, Beal, Benatti, Bonda, Breese, Carpenedo, Carpenedo, Casazza, Castellano, Ceresoli-Borroni, Cesura, Chess, Chess, Chess, Chiarugi, Chiarugi, Clark, Cochran, Cozzi, Cui, Daily, Dalley, Dantzer, Darlington, Darlington, Davidson, Deiana, Della Torre, DiNatale, Dobelis, Dounay, Eastman, Erhardt, Forrest, Forrest, Forrest, Forrest, Fukui, Gellert, Giordani, Giorgini, Gold, Graef, Guidetti, Guidetti, Guidetti, Guidetti, Guillemin, Guillemin, Hardingham, Hedges, Henderson, Heng, Hernandez, Heyes, Hilmas, Holtze, Jason, Jauch, Jentsch, Jurgens, Kalisch, Kandanearatchi, Kiank, Kihara, Kloet, Kocki, Konradsson-Geuken, Lawrence, Lawrence, Linderholm, Lindsley, Luchowski, Luchowski, Lupien, Marin, Mexal, Millan, Miller, Minzenberg, Miura, Moeller, Mok, Muchowski, Muchowski, Mueller, Muscatell, Myint, Nagy, Neill, Newcomer, Newcomer, Nilsson, Nilsson, Nozaki, O'Connor, Olsson, Onur, Owe-Young, Paterson, Pearson, Pechtel, Pellicciari, Pellicciari, Perkins, Pertovaara, Pevarello, Phillips, Pocivavsek, Pocivavsek, Popoli, Popoli, Potter, Rahman, Raison, Rassoulpour, Ren, Robert, Rodgers, Rossi, Ryu, Röver, Saito, Salazar, Sapko, Sarter, Sathyasaikumar, Sathyasaikumar, Schwarcz, Schwarcz, Schwarcz, Schwarcz, Shear, Speciale, Speciale, Stazka, Stazka, Stone, Stone, Stone, Stone, Stone, Stoy, Tadaiesky, Tatter, Teichberg, Teichberg, Ting, Trecartin, Tse, Varasi, Vezzani, Walker, Wang, Wang, Wejksza, Wejksza, Wonodi, Xu, Yamada, Yuen, Zisapel, Zmarowski   +172 more
core   +1 more source

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal of Immunotherapy for Cancer, 2018
BackgroundIndoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer.
Asha Nayak-Kapoor, Zhonglin Hao, Ramses F. Sadek, Robin Dobbins, L. Marshall, N. Vahanian, W. Jay Ramsey, E. Kennedy, M. Mautino, C. Link, R. Lin, S. Royer-Joo, Xiaorong Liang, L. Salphati, K. Morrissey, S. Mahrus, B. McCall, A. Pirzkall, D. Munn, J. Janik, S. Khleif   +20 more
semanticscholar   +1 more source

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Translating Metabolic Reprogramming into New Targets for Kidney Cancer. [PDF]

, 2017
In the age of bioinformatics and with the advent of high-powered computation over the past decade or so the landscape of biomedical research has become radically altered.
Abu Aboud, Omran, Weiss, Robert H
core   +1 more source

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Clinical Cancer Research, 2019
Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg).
Kyung Hae Jung, P. LoRusso, H. Burris, M. Gordon, Y. Bang, M. Hellmann, A. Cervantes, M. O. de Olza, A. Marabelle, F. Hodi, M. Ahn, L. Emens, F. Barlesi, O. Hamid, E. Calvo, D. McDermott, H. Soliman, I. Rhee, R. Lin, T. Pourmohamad, Julia Suchomel, A. Tsuhako, K. Morrissey, S. Mahrus, R. Morley, A. Pirzkall, S. Lindsey Davis   +26 more
semanticscholar   +1 more source

Vitamin e-loaded membrane dialyzers reduce hemodialysis inflammaging

BMC Nephrology, 2019
Background Inflammaging is a persistent, low−grade, sterile, nonresolving inflammatory state, associated with the senescence of the immune system. Such condition downregulates both innate and adaptive immune responses during chronic disorders as type II ...
Vincenzo Sepe, Marilena Gregorini, Teresa Rampino, Pasquale Esposito, Rosanna Coppo, Francesco Galli, Carmelo Libetta   +6 more
doaj   +1 more source

Evaluation of mode of indoleamine 2,3-dioxygenase 1 inhibition by 4,7-dichloroquinolines

European Journal of Medicinal Chemistry Reports, 2023
Herein, we report the development of synthetically simpler analogs of 4,7-dichloroquinoline (DCQ) as apo-indoleamine 2,3-dioxygenase 1(IDO1) protein targeting ligand to inhibit the activity of IDO1 enzyme.
Niku Moni Das, Biswa Mohan Prusty, Nirmalya Pradhan, Anjali Gupta, Miguel Carmena-Bargueño, Rama Karn, Horacio Pérez-Sánchez, Sachin Kumar, Debasis Manna   +8 more
doaj   +1 more source